These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 25130688)
1. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study. Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688 [TBL] [Abstract][Full Text] [Related]
2. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience]. Badowska W Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816 [TBL] [Abstract][Full Text] [Related]
4. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416 [TBL] [Abstract][Full Text] [Related]
6. Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057 [TBL] [Abstract][Full Text] [Related]
7. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic]. Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]. Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561 [TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029 [TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. Pichler H; Möricke A; Mann G; Teigler-Schlegel A; Niggli F; Nebral K; König M; Inthal A; Krehan D; Dworzak MN; Janousek D; Harbott J; Schrappe M; Gadner H; Strehl S; Haas OA; Panzer-Grümayer R; Attarbaschi A; Br J Haematol; 2010 Apr; 149(1):93-100. PubMed ID: 20067563 [TBL] [Abstract][Full Text] [Related]
11. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity]. Karachunskiĭ AI; Miakova NV; Rumiantseva IuV; Timakov AM; Makhortykh TZh; Fechina LG; Shamardina AV; Dudkin SA; Lebedev VV; Varfolomeeva SR; Timofeeva VN; Herold R; Stakelberg A; Henze G; Rumiantsev AG Ter Arkh; 2007; 79(7):19-26. PubMed ID: 17802785 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of dose-adjusted Berlin-Frankfurt-Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma. Xie Y; Zhang Y; Zheng W; Wang X; Lin N; Tu M; Ping L; Ying Z; Zhang C; Liu W; Deng L; Song Y; Zhu J Med Oncol; 2015 Apr; 32(4):110. PubMed ID: 25752875 [TBL] [Abstract][Full Text] [Related]
13. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119 [TBL] [Abstract][Full Text] [Related]
14. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis. El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of acute lymphoblastic leukemia in adults as an unsolved problem]. Savchenko VG; Parovichnikova EN; Isaev VG; Kulimova EP; Kucher RA; Sokolov AN; Ustinova EN; Gribanova EO; Khoroshko ND; Pivnik AV; Tikhonova LIu; Sarkisian GP; Domracheva EV; Maslova ER; Konstantinova TS; Rekhtman GB; Lapin VA; Miliutina TI Ter Arkh; 2001; 73(7):6-15. PubMed ID: 11523412 [No Abstract] [Full Text] [Related]
16. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers. Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894 [TBL] [Abstract][Full Text] [Related]
17. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary]. Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956 [TBL] [Abstract][Full Text] [Related]
18. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type]. López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701 [TBL] [Abstract][Full Text] [Related]
19. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol. Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]